Tonix Pharmaceuticals Holding Corp. (TNXP)
Healthcare · NMS
Fundamentals
Valuation and ratings
Tonix Pharmaceuticals Holding Corp. trades at USD9.88, which is 62% below the USD15.99 our discounted cash flow model puts on the business. On that measure alone it screens as undervalued, though a DCF is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 40 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
TNXP dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
TNXP earnings and analyst estimates
Recommendation mix, 4 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
TNXP passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
4 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$6.44M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$3.02M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$2.22M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$1.72M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Tonix Pharmaceuticals Holding Corp. (TNXP) undervalued?
Against our discounted cash flow estimate of USD15.99, TNXP at USD9.88 is 62% below fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own TNXP?
4 of the institutions we track reported a position in TNXP in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
When does TNXP report earnings next?
Tonix Pharmaceuticals Holding Corp. is scheduled to report on 10 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for TNXP, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.